| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer.
Looking at options history for Pfizer (NYSE:PFE) we detected 18 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $635,420 and 15, calls, for a total amount of $588,190.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $31.0 for Pfizer, spanning the last three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $25.0 to $31.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | PUT | SWEEP | BEARISH | 01/17/25 | $0.69 | $0.61 | $0.66 | $25.00 | $327.5K | 58.9K | 5.0K |
| PFE | PUT | TRADE | BULLISH | 06/07/24 | $0.19 | $0.18 | $0.18 | $28.00 | $241.9K | 1.6K | 14.4K |
| PFE | CALL | SWEEP | BULLISH | 06/07/24 | $0.3 | $0.29 | $0.3 | $30.00 | $95.5K | 2.4K | 6.7K |
| PFE | PUT | SWEEP | BEARISH | 01/17/25 | $0.66 | $0.62 | $0.66 | $25.00 | $66.0K | 58.9K | 7.0K |
| PFE | CALL | SWEEP | BULLISH | 06/07/24 | $0.19 | $0.17 | $0.18 | $30.00 | $56.4K | 2.4K | 3.2K |
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
In the last month, 2 experts released ratings on this stock with an average target price of $32.5.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.
Posted In: PFE
